New Platform Hopes To Speed Diagnosis Of Parkinson's Disease And Breast Cancer, Oxford Impedance Diagnostics Reveals

Oxford Impedance Diagnostics, a spin-out from the University of Oxford, in Oxford, UK, is commercializing an ultrasensitive rapid diagnostic test for Parkinson’s disease, breast cancer, a range of infectious diseases and several cardiovascular health conditions.

The company was cofounded by Professor Jason Davis from Oxford University and Professor Paulo Bueno, Sao Paulo State University, Brazil and has raised £2m in seed funding from investors including Oxford Technology Investment Fund, Oxford Sciences Innovation, Bio-Rad Laboratories Inc. and several angel investors.

Back to news